Register

Medical Oncology

Non-small cell lung cancer   

Questions discussed in this category

Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
1 Answer available
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Can you explain the expansion cohorts into larger trials and the current amendments to the the protocol?
1 Answer available
What is the preferred second line, systemic therapy for NSCLC patients following first line chemoimmunotherapy?
How does the changing landscape of first-line treatment impact your decision making for second line therapy?
9 Answers available
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
2 Answers available
Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?
2 Answers available
Do you consider NSCLC with multistation N2 involvement appropriate for treatment with neoadjuvant chemoimmunotherapy followed by surgery?
6 Answers available
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
1 Answer available
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...
4 Answers available
How many days do you hold osimertinib during or around SBRT for oligometastatic EGFR mutated advanced lung cancer?
Does the site of treatment factor into your decision? 
2 Answers available
How would you approach Grade 2-3 rash due to erlotinib for a patient with metastatic EGFR mutated lung adenocarcinoma that is well controlled for > 5 years and NED by PET?
1 Answer available
How are you approaching patients with early-stage NSCLC who progress on neoadjuvant chemo-immunotherapy and are no longer surgical candidates?
5 Answers available
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
1 Answer available
What is your approach to adjuvant therapy for an R0, ALK+ resected lung adenocarcinoma with N2 disease?
1 Answer available
How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?
The left breast cancer is an ER-negative, PR-negative, HER2-negative cT2N0 invasive ductal carcinoma, while the left lung primary is a cT2N1 squamous ...
5 Answers available
Would you offer a different ALK inhibitor to a patient receiving alectinib who had decompensation of liver function in the setting of preexisting cirrhosis?
1 Answer available
Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?
If so, when and to what extent? 
2 Answers available
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?
1 Answer available
Is there ever a role for adjuvant chemotherapy and/or immunotherapy for early stage, N0 non-small cell lung cancer treated with SBRT alone?
5 Answers available
Do you prefer cisplatin or carboplatin in combination with nivolumab per CheckMate 816 for patients with resectable NSCLC?
Based on subgroup analysis, do you have a preference for cisplatin over carboplatin? 
1 Answer available
Would you consider using sotorasib first line in patient with metastatic KRAS G12C NSCLC who declines chemotherapy?
3 Answers available
What are your top takeaways in Thoracic Cancers from ASCO 2023?
5 Answers available
Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?
Do you ever consider bridging with chemotherapy, and if so for how long? 
1 Answer available
How do you decide between checkpoint monotherapy versus chemo-immunotherapy approach for patients with PD-L1 High (>50%) NSCLC?
IMPower110 data add further support to use of checkpoint monotherapy; however guidelines continue to support either I/O monotherapy vs chemo-immunothe...
7 Answers available
What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?
Assuming the patient had no contraindications to immunotherapy and no other significant comorbidities.
1 Answer available
How do you define an adequate EBUS when staging NSCLC?
Is there a minimum standard for which stations to sample? Does lymph node size affect your recommendations?
3 Answers available
Are you treating patients with RET-fusion+ metastatic NSCLC with RET inhibitors as the first line of therapy regardless of PD-L1 expression?
Are there scenarios in which you would proceed with checkpoint inhibitor for PDL1+ disease before having full molecular testing results?
5 Answers available
For NSCLC patients with limited diagnostic tissue that is insufficient for genetic testing, do you offer repeat biopsy (of accessible site), blood based testing, or both to evaluate for actionable driver mutations?
3 Answers available
What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?
5 Answers available
Do you consider using 160 mg osimertinib in patients with EGFR-positive metastatic NSCLC to the brain?
1 Answer available
How would you treat a potentially resectable stage III lung adenocarcinoma with an EGFR mutation?
Do you consider any neoadjuvant therapy or proceed to surgery followed by adjuvant chemotherapy and osimertinib? Does the type of mutation (ex a rare ...
1 Answer available
What is your current practice for obtaining PD-L1 and mutation testing for newly diagnosed metastatic NSCLC?
What specific platforms do you use, individual biomarker/PD-L1 status vs NGS, tissue vs liquid or both? Must you wait for PD-L1 testing if mutation t...
6 Answers available
Are PD-L1 and molecular markers from pleural fluid specimens reliable enough to guide decision making in metastatic NSCLC?
Or would you conduct tissue or blood testing if no actionable results are found? 
4 Answers available
Would you send a lung cancer patient for genetic counseling/germline mutation testing if they are harboring mutations in NGS with variation allele frequency between >=50%?
Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients that have been...
4 Answers available
Do you ever start immunotherapy along with WBRT in patients with PDL1 >50% metastatic NSCLC with significant visceral tumor burden in addition to symptomatic brain mets?
4 Answers available
How do you approach a patient with discordant mutation testing in liquid vs tissue biopsy for mNSCLC?
4 Answers available
For patients with NSCLC on osimertinib who progress, would you continue osimertinib when moving onto chemotherapy for 2nd line therapy?
1 Answer available
Based on results from ADAURA, in clinical practice, how likely are you to recommend adjuvant chemotherapy prior to adjuvant osimertinib for stage IIA T2bN0 EGFR mutant NSCLC?
1 Answer available
How do you decide which immunotherapy agent to utilize for 1st line in PD-L1 high (>50%) NSCLC?
Are there specific clinical factors, efficacy, or treatment tolerability issues that lead you to favor one agent over another? How do you compare or ...
8 Answers available
Do you see any role for PARP inhibitors in NSCLC given the recent PIN trial of maintenance olaparib did not show significant improvement in PFS?
Based on results of the recently published study. 
1 Answer available
What is your approach and preferred first line treatment regimen for advanced/metastatic adenosquamous NSCLC?
1 Answer available
What adjuvant therapy would you offer following adjuvant chemotherapy for a patient with Stage III lung adenocarcinoma with an atypical EGFR mutation such as EGFR L861R?
Would you offer adjuvant atezolizumab, osimertinib, or neither? Both IMpower010 and ADAURA only had patients with EGFR exon 19 deletion or L858R mutat...
1 Answer available
Should durvalumab consolidation still be offered to Stage III NSCLC patients with PD-L1< 1%?
Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?
3 Answers available
Should IMPower010 results be extrapolated to superior sulcus tumors treated with chemoradiation and surgery?
1 Answer available
For patients with KRAS G12C mutated NSCLC, how would you decide between using targeted therapy with sotorasib vs adagrasib?
Is there anything to differentiate the two agents? CNS penetration reportedly with adagrasib, FDA accelerated approval has been given with sotorasib.&...
2 Answers available
How do you choose between neoadjuvant chemotherapy alone vs neoadjuvant chemoradiation in patients with potentially resectable stage III NSCLC who are not upfront surgical candidates?
1 Answer available
Do you hold or avoid pemetrexed in patients with NSCLC and pleural effusions?
1 Answer available
Would you ever consider definitive thoracic RT with concurrent immunotherapy in Stage III NSCLC?
I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...
2 Answers available
How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?
How do you operationalize finding biomarker information in EHRs/testing portals, either for your own patients or if they have changed providers? If a...
4 Answers available
What are your treatment considerations for a patient with stage IVb NSCLC who is KRAS G12C mutated and PD-L1 high (>50%)?
3 Answers available
Are there best practices for managing or mitigating toxicity from sotorasib such as hyperbilirubinemia or edema?
3 Answers available
Do you offer durvalumab to patients with stage IIIB NSCLC after chemoradiation if they are also on long term dialysis for ESRD?
Are there data for using checkpoint inhibitors in this setting? 
1 Answer available
Which patients with resectable Stage IB-IIIA NSCLC would most benefit from using neoadjuvant chemoimmunotherapy as per CheckMate 816?
1 Answer available
What are best practices for engaging with multidisciplinary colleagues to ensure patients with earlier stage NSCLC are being appropriately considered for novel adjuvant therapies?
How are your teams effectively evaluating and counseling patients to ensure they are prepared for potential extended adjuvant treatment approaches? Is...
4 Answers available
Would you extrapolate IMPower010 data to offer adjuvant atezolizumab to a patient with N2 PDL1-high (>50%) NSCLC who had been treated with induction chemotherapy followed by definitive R0 resection after partial response?
Can atezo be used even if patient has completed chemotherapy preoperatively?
2 Answers available
What is your preferred first line treatment approach for a patient with PDL-1 high (>50%) NSCLC presenting with CNS mets?
If a patient is asymptomatic at presentation, how do you incorporate local treatment options (RT/surgery) and when?
2 Answers available
What high risk features for stage IB NSCLC would lead you to consider adjuvant chemotherapy?
Do you consider size > 2cm, visceral pleural invasion or vascular invasion as indications for cisplatin-based chemotherapy? 
2 Answers available
Would you hold osimertinib in a patient with a STEMI, and for how long?
1 Answer available
Are there any data for second line nivolumab-ipilimumab in patients with metastatic NSCLC treated with either single agent pembrolizumab or chemotherapy + ICI as first line therapy?
Would you consider second line nivo-ipi for patients with a specific histology or tumor PD-L1 expression? 
1 Answer available
How would use of adjuvant atezolizumab for PDL1+ NSCLC potentially impact your treatment choice at recurrence?
Is there a certain time interval where you would feel comfortable to rechallenge with immunotherapy at recurrence (6m vs 1y vs 2y?) Does degree of PDL...
2 Answers available
Should 1 year of atezolizumab be the standard of care for stage II-IIIA resected PDL1+ NSCLC?
Are the experts convinced by DFS when the OS is immature?  How many in BSC arm went on to receive immunotherapy and was that adequate?
2 Answers available
What is your recommended adjuvant approach to resected NSCLC with both PD-L1>1% and EGFR mutation?
What would you do for a patient with a non-EGFR actionable mutation?IMpower010 included EGFR and ALK mutated NSCLC. Is there any concern in the use of...
2 Answers available
How do you approach patients with Stage IIIB/C NSCLC with ipsilateral supraclavicular (N3) disease?
Do you initially start with systemic therapy alone or do you proceed directly to chemo-radiation? 
1 Answer available
Are there clinical features that would lead you to consider combining SBRT + immunotherapy in a high risk early stage NSCLC?
1 Answer available
Are you selecting any specific patient cohort with metastatic NSCLC for treatment with the CheckMate 9LA protocol of ipilimumab + nivolumab + 2 cycles of chemotherapy?
5 Answers available
What is your preferred first line regimen for PDL1-negative squamous cell lung cancer?
What is your general rationale for selecting from available options?
6 Answers available
What factors do you take into account for recommending chemo/IO vs IO/IO vs CheckMate 9LA regimen in front line therapy for PD-L1 negative advanced squamous cell carcinoma?
How do you interpret the comparative efficacy in squamous cell subsets among the CM vs KN vs EMPOWER studies?
4 Answers available
Do you avoid immunotherapy in patients with Stage IV NSCLC with atypical EGFR mutations such as G719S or S768I?
1 Answer available
How do you approach EGFR mutated NSCLC with isolated progression in the chest who is planned for a course of radiation at least 3-4 weeks?
How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?
1 Answer available
How would you treat a patient with stage 4 NSCLC with EGFR R776H mutation?
2 Answers available
Do you have a maximum size cutoff for lung SBRT in central NSCLC?
E.g. for a 7cm central NSCLC, would you offer 8 fx SBRT or ChemoRT? Patient is not a surgical candidate.
6 Answers available
What would you offer as adjuvant therapy for a resected stage IIIB adeno NSCLC in a patient who refuses chemotherapy?
Can adjuvant durvalumab or other I/O or osimertinib (if EGFR+) be considered?
2 Answers available
How do you approach patients with driver mutation positive, Stage IV NSCLC who don't benefit from upfront first-line TKI?
Although a small subset, do you generally move these patients directly on to chemotherapy +/- immunotherapy or does it depend on the specific mutation...
1 Answer available
Are there specific ROS1 fusions/mutations that confer sensitivity or resistance to therapy to help guide treatment selection in first line or at progression?
3 Answers available
How would you treat a patient with squamous NSCLC with NRG1 amplification (no fusion) who has progressed on first-line treatment?
Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear. 
2 Answers available
When giving single agent docetaxel for patients with metastatic NSCLC who have progressed on platinum and immunotherapy, do you stop after 6 cycles or do you continue as long as tolerated and disease is stable?
1 Answer available
What is your approach to a patient with an EGFR exon 19 mutated NSCLC who develops progression on osimertinib and repeat biopsy demonstrates the EGFR exon 19 mutation and a new BRAF V600E mutation?
1 Answer available
For a patient with metastatic NSCLC, PD-L1>50%, after progression on first line checkpoint inhibitor, do you prefer chemotherapy alone or chemotherapy added to the immunotherapy?
9 Answers available
What is your preferred first line therapy in metastatic ALK+ NSCLC?
The ALTA and ALEX trials showed better PFS with brigatinib v. crizotinib and alectinib v. crizotinib. How do you choose your first...
6 Answers available
How do you approach treatment for patients with ALK+ mNSCLC who have multifocal or leptomeningeal CNS progression while on first-line targeted therapy?
Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?
5 Answers available
How do you manage ALK-inhibitor AEs which are low grade but significantly impact patient QOL over time?
Such as dysgeusia, headache, rash, fatigue, etc
4 Answers available
How can you adjust neoadjuvant or adjuvant platinum based chemotherapy for stage Stage II-III non-small cell lung cancer in patients with significant renal insufficiency?
2 Answers available
In locally advanced EGFR-mutated NSCLC with initial good response to osimertinib, how do you manage local progression of the primary?
Would you consider SBRT and continue osimertinib?
2 Answers available
How do you approach missed doses of durvalumab consolidation in patients with Stage III NSCLC?
Do you aim to give a total of 26 doses or do you stop at one year from first dose no matter how many were given?
1 Answer available
Is there a preferred ALK targeting agent for patients with ALK+ mNSCLC presenting with CNS metastases?
2 Answers available
Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFRm NSCLC?
6 Answers available
For patients with early stage resected giant cell lung cancer and other less common histologies, are there any specific considerations for adjuvant therapy?
1 Answer available
How do you approach patients with unresectable NSCLC planned for concurrent chemoradiation who develop a serious infusion reaction to paclitaxel?
1 Answer available
Would you consider maintenance immunotherapy following chemoradiation for a patient with an isolated mediastinal recurrence of NSCLC?
1 Answer available
How would you approach metastatic NSCLC (adenocarcinoma without brain mets) with PD-L1 >50% and BRAF V600E driver mutation?
2 Answers available
How would you treat oligometastatic NSCLC (brain and bone) with Non-V600E BRAF mutations?
SRS done to the single brain met, PD-L1 5%,  BRAF G469A mutation
1 Answer available
How would you treat a patient with metastatic NSCLC with repeated episodes of CNS brain metastases but otherwise with good systemic disease control on maintenance therapy?
The patient remains without evidence of systemic disease outside of the CNS on serial imaging. Would you continue treating with SRS as lesions appear,...
2 Answers available
Would you offer systemic therapy after rendered NED from SRS to isolated CNS metastases in a patient with prior curative intent treatment of lung adenocarcinoma and clear cell RCC?
1 Answer available
How do you manage pneumonitis in patients with Stage III NSCLC receiving durvalumab?
How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...
2 Answers available
Are there any subsets of patients where you would consider first-line dacomitinib for EGFR mutations positive NSCLC?
Are there specific mutations or co-mutations were you would consider use of this agent? 
1 Answer available
Would you offer EGFR inhibitors to a patient with metastatic lung adenocarcinoma EGFR L858R mutation and concomitant NRAS mutation both on blood based testing?
1 Answer available
In patients with metastatic lung SCC who are on pembrolizumab maintenance after starting pembrolizumab/carboplatin/nab-paclitaxel, what is your treatment strategy if they progress while on pembrolizumab alone?
Would you continue pembrolizumab with a re-challenge with carboplatin/taxane or move to second line therapy?
4 Answers available
Should we consider deferring adjuvant chemotherapy for resected early-stage NSCLC in light of COVID-19?
If so, how long is too long to wait?
1 Answer available
Would you discontinue dabrafenib/trametinib in a patient with BRAF mutant metastatic lung cancer if you see mild cardiomyopathy which could be related to the drugs?
Patient does not want chemo but is tolerating these well otherwise. 
1 Answer available
How do you counsel patients with metastatic NSCLC who have a sustained response (> 2 years) to checkpoint inhibitors who wish to discontinue therapy?
How do you approach this given the limited # of patients this applies to?  Checkmate 017 and 057 only had 5-7% of patients still on nivolumab at ...
4 Answers available
Do patients with Stage III unresectable NSCLC with lepidic features require a different approach to chemo-radiation?
Would your choice of concurrent chemotherapy be impacted by this histologic finding? 
0 Answers available
Do you offer consolidative thoracic radiation for oligometastatic NSCLC following upfront immunotherapy?
In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...
2 Answers available
Would you rather start radiation for Stage III NSCLC in the middle of a chemotherapy cycle or wait for the 2nd cycle if it could not be started on cycle 1 day 1?
1 Answer available
How would you manage a patient with no driver mutation, PD-L1 <50%, with systemic relapse of lung adenocarcinoma within a year after resection and completion of adjuvant platinum based chemotherapy?
Would you consider single agent immunotherapy given recent exposure to platinum agent or chemoimmunotherapy?
2 Answers available
How do you approach patients for definitive chemoradiation in locally advanced NSCLC who have severe neuropathy?
Are the other options of chemotherapy that can be used instead of platinum based doublets, including with paclitaxel? 
2 Answers available
How long do you continue surveillance imaging for NSCLC after definitive treatment?
NCCN recommends annual CT surveillance indefinitely after year 5, but I’m curious how many physicians continue and for how long?
3 Answers available
How do you decide between carboplatin vs not recommending adjuvant chemotherapy entirely for patients with resected NSCLC with relative or absolute contraindications to cisplatin?
 ie renal dysfunction, hearing loss, neuropathy
1 Answer available
Would you deliver SRS/XRT for isolated asymptomatic CNS metastasis before start of immunotherapy for stage IV lung cancer (negative for driver mutation) with high positive PDL1?
1 Answer available
Do you consider additional chemotherapy or durvalumab after definitive concurrent chemo/RT for Stage II NSCLC for patients who are not surgical candidates?
Would PDL-1 status impact your decision?
3 Answers available
How do you approach elderly patients with stage III NSCLC who have a reasonable performance status?
Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?
1 Answer available
Aside from MET exon 14 skip mutations, are there other targetable MET mutations or fusions that you would consider for TKI therapy?
Would you reserve TKI for after standard of care chemotherapy and immunotherapy or consider earlier line of treatment?
1 Answer available
Do you offer consolidation chemotherapy prior to durvalumab in locally advanced, unresectable NSCLC?
In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial.Antonia et al., PMID 28885881...
3 Answers available
How do you monitor response for stage III NSCLC patients receiving consolidation immunotherapy?
CT or PET? If so, how often?
3 Answers available
Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?
Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.
2 Answers available
For patients with inoperable stage III NSCLC who are unable to receive or refuse definitive chemoradiation, how do you decide among radiation alone, pembrolizumab alone, or radiation followed by either pembrolizumab or durvalumab?
5 Answers available
How do you time re-staging studies and adjuvant durvalumab for stage III NSCLC treated with definitive cCRT?
Do you feel it is important to start durvalumab within 14 days of completing cCRT?  What real life challenges do you face in doing so and wh...
1 Answer available
What are the clear criteria for unresectability in locally advanced NSCLC patients, other than medical or anatomic?
Medical inoperability is clearly defined, anatomical resectability is also pretty much clear (invasion of trachea/carina/esophagus, etc). But what abo...
1 Answer available
Do you stop consolidative durvalumab after one year as per the PACIFIC trial or continue if the patient is otherwise tolerating well?
1 Answer available
Would you offer the PACIFIC protocol to a patient with stage III lung cancer with performance status 2-3?
If so, how would you modify this regimen?
1 Answer available
If you are treating a patient with palliative radiation for hemoptysis do you require chemotherapy to be held?
If you are using a standard 30/10 fractionation, is there a benefit to keeping chemo on board for radio-sensitization?
4 Answers available
For stage III NSCLC treated with definitive intent chemoRT, how do you decide to proceed with surgery vs consolidation immunotherapy?
1 Answer available
What would be your approach in a patient with MET amplification and PDL-1 80% expression?
Do you use crizotinib for first-line therapy?
1 Answer available
How are you treating patients who progress while on durvalumab after definitive chemoradiation for stage III NSCLC?
Is the timing of progression (in relation to chemoradiation) a factor, and is there any role for repeat PD-L1 testing at the time of progression?
2 Answers available
Do you consider MET amplification in your first-line treatment decisions for patients with metastatic NSCLC?
1 Answer available
When do you recommend broader molecular testing for clinical trials in stage IV NSCLC patients who have negative initial molecular testing for FDA-approved targetable mutations?
0 Answers available
Would you resume durvalumab after several month hiatus due to IO unrelated medical comorbidities that has since resolved?
If it is still within the 12 month period and no disease recurrence?
3 Answers available
How do you decide between enrolling an oligometastatic NSCLC patient on LU-002 versus treating them with SBRT off trial?
Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to ...
1 Answer available
Would you offer upfront osimertinib rather than whole brain irradiation for a patient with stage IV, EGFR exon 19 mutated lung adenocarcinoma who presents with leptomeningeal metastases?
1 Answer available
Should radiotherapy be utilized in stage IVA NSCLC with a malignant pericardial effusion?
If there is no other evidence of metastatic disease, would you offer thoracic radiation? Either upfront with chemo or after initial system therapy if ...
1 Answer available
For oligometastatic NSCLC that would be otherwise considered stage 3, would you consider consolidative immunotherapy with durvalumab after definitive treatment for both the primary and oligometastatic site?
2 Answers available
What would you choose as the second line treatment option for a stage IV EGFR mutant lung adenocarcinoma that has progressed on osimertinib?
Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?
1 Answer available
What is the role of upfront pembrolizumab in metastatic PD-L1 positive NSCLC presenting with SVC syndrome?
Would starting with chemotherapy be preferred in this situation and consider concurrent radiation, then switch over to Pembrolizumab once some control...
1 Answer available
Would you offer immunotherapy after chemoradiotherapy for Stage III lung cancer given results of PACIFIC Trial?
If so how would you select patients (ie. PS, histology, PD-L1 expression level)? 
2 Answers available
Do you ever recommend PORT or chemoRT rather than chemotherapy alone for NSCLC with adverse features other than positive margins or N2 disease?
For example, would a + vascular margin, extranodal extension of N1 disease, translobar disease, or high risk histologies (large cell neuroendocrine, s...
2 Answers available
What is your preferred first line approach to patients with good PS stage IV non-squamous NSCLC that is EGFR/ROS1/ALK/BRAF WT and PDL-1 < 1%?
Do you prefer carboplatin-paclitaxel-bevacizumab, carboplatin-pemetrexed-pembrolizumab, or chemotherapy alone?
2 Answers available
What is the role of "adjuvant" systemic chemotherapy in patients previously resected NSCLC, now with isolated solitary relapsed brain lesion, treated with resection and SBRT?
Is there any data for the benefit for systemic chemo in such situation?
1 Answer available
How do you decide on the sequence of systemic and local therapy for patients with oligometastatic NSCLC?
When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?
1 Answer available
When do you recommend induction chemotherapy prior to concurrent chemoradiotherapy for locally advanced NSCLC?
If you treat pre-chemotherapy volumes, is there a benefit to induction chemotherapy even in bulky disease. If so, how do you define disease that ...
2 Answers available
Do you recommend concurrent or sequential radiation and chemotherapy for margin-positive, node negative NSCLC?
What factors influence your decision (R1 v. R2 resection? T stage?) If sequential, do you typically prefer radiation before or after chemotherapy?
2 Answers available
Do you use a TKI for resected EGFR+ non-small cell lung cancer?
In IB-IIIA cases?
1 Answer available


Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-09-01
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-01
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
Medical and pediatric oncology, 1990
Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986-01
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
N Engl J Med, 2017 Nov 16
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2015-10-22
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Lancet (London, England), 2017-01-21
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
The Lancet. Oncology, 2016-11
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
The New England journal of medicine, 2018-05-31
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
J. Clin. Oncol.,
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
The New England journal of medicine, 2016-11-10
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2017-06-22
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2018-12-13
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Pulmonary medicine, 2012
Novel insights of oligometastases and oligo-recurrence and review of the literature.
Radiat Oncol, 2015 Apr 26
Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-12-10
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Lancet (London, England), 2014-08-23
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
The New England journal of medicine, 2018-06-14
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Lancet Oncol, 2019 May 20
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
J Clin Oncol, 2022 Jun 03
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-09-01
Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2018-11-22
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
The Lancet. Oncology, 2017-07
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
International journal of radiation oncology, biology, physics, 2017-06-01
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
JAMA oncology, 2018-01-11
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
J Thorac Oncol, 2018 Feb
Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy.
The New England journal of medicine, 2017-08-31
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Ann Oncol, 2020 May 11
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
N Engl J Med,
First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer.
J Clin Oncol, 2020 Aug 11
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
J Thorac Oncol,
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
The Lancet. Respiratory medicine, 2017-11
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Lancet (London, England), 2009-08-01
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Lung Cancer,
Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.
Lancet Oncol., 2008 Jun 24
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.
JAMA oncology, 2017-05-01
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
J. Clin. Oncol., 2015 Nov 02
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
International journal of radiation oncology, biology, physics, 2015-09-01
Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
Future Oncol, 2019 Apr 25
Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.
J Clin Oncol, 2023 Jan 31
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Lancet (London, England), 2023 Jul 18
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Lancet (London, England), 2023 Jul 18
Safe and effective systemic therapy for early-stage non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-11-01
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-01
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Lancet (London, England), 2016-04-09
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Clin. Cancer Res., 2018 Oct 08
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.
International journal of radiation oncology, biology, physics, 2018-03-15
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
J Thorac Oncol, 2019 Feb 16
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
The New England journal of medicine, 2011-08-04
Reduced lung-cancer mortality with low-dose computed tomographic screening.
The Journal of molecular diagnostics : JMD, 2018-03
Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma.
Ann Oncol, 2020 Feb 06
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
Acta Cytol, 2021 Jul 07
PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.
Lancet Oncol., 2012 May 22
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).
J. Clin. Oncol., 2019 Dec 11
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Lancet Oncol., 2017 Sep 25
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
The New England journal of medicine, 2014-11-13
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Lancet Oncol., 2017 Sep 11
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-10
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
N Engl J Med, 2020 Sep 19
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
J Clin Oncol, 2020 Dec 04
Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
J Thorac Dis,
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
Ann. Oncol., 2015 Apr 28
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
J Clin Oncol, 2020 Sep 10
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Lung cancer (Amsterdam, Netherlands), 2017-10
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Curr Oncol, 2020 May 01
Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.
Mol Cancer, 2020 Sep 11
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook.
PLoS One, 2018 Aug 28
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-11-01
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-20
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
JCO precision oncology, 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-01
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Annals of oncology : official journal of the European Society for Medical Oncology, 2016-07
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Clin Lung Cancer, 2020 Feb 10
Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
JTO Clin Res Rep, 2020 May 13
Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC.
Clin Oncol (R Coll Radiol), 2017 Nov 16
Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06
Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.
Radiother Oncol, 2020 Jul 31
An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.
The New England journal of medicine, 2018-11-22
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Lancet, 2017 Jan 24
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
The Lancet. Oncology, 2014-09
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Cancer Sci,
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
The Lancet. Oncology, 2015-07
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
The Lancet. Respiratory medicine, 2019-05
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
N. Engl. J. Med., 2019 Sep 28
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
ESMO Open, 2021 Oct 01
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
J Clin Oncol, 2021 Apr 19
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Lancet Oncol, 2021 Jan 18
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
N Engl J Med,
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Lancet,
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Ann. Oncol.,
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-08
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
J Thorac Oncol, 2021 Jul 08
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
Lancet (London, England), 2019-05-04
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
J Clin Oncol, 2021 Jan 29
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
J BUON,
Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape.
Br J Cancer, 2019 Sep 30
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
The New England journal of medicine, 2005-06-23
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
Lancet Oncol., 2006-09-01
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
J. Clin. Oncol., 2008-07-20
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
The Lancet. Oncology, 2017-12
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
N. Engl. J. Med.,
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
JAMA, 2010-03-17
Stereotactic body radiation therapy for inoperable early stage lung cancer.
International journal of radiation oncology, biology, physics, 2015-06-01
Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
Chest, 2003-11
Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer.
The Lancet. Oncology, 2017-01
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-20
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
JAMA Oncol,
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Clin Lung Cancer, 2021 Jan 27
Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
Eur J Cancer, 2021 Apr 01
Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Lancet Oncol, 2019 Oct 25
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Biochemistry, 2015 Jul 06
Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.
N Engl J Med, 2019 Nov 21
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.
Lancet Oncol, 2016 Apr 12
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-01
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Future Oncol, 2018 Nov 08
Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
World J Clin Cases,
Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.
Br J Cancer, 2016 Nov 22
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2011-10-01
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
Lung Cancer, 2020 Nov 13
Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.
Neuropathology, 2019 Mar 13
Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: An autopsy report.
Respir Investig, 2014 Nov 13
Disease flare after gefitinib discontinuation.
Lancet, 2021 Sep 20
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-04
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
J Thorac Oncol, 2021 May 05
Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis-the META-L-BRAIN Study.
JACC CardioOncol, 2019 Dec 17
Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).
N Engl J Med, 2022 Apr 11
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Clin Cancer Res, 2010 May 11
Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Cancer Chemother Pharmacol, 2014 Jun 17
Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.
N Engl J Med, 2022 Jun 03
Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.
Oncology, 2020 May 28
The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
Ann Oncol, 2022 Feb 14
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
FEBS J, 2009 Nov 18
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.
Clin Lung Cancer, 2018 May 01
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
J Thorac Oncol, 2021 Feb 01
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
N Engl J Med, 2021 Jun 04
Sotorasib for Lung Cancers with p.G12C Mutation.
EClinicalMedicine, 2022 Aug 11
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.
The Lancet. Oncology, 2015-02
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Eur Respir J, 2005 Aug
Morbidity and mortality in the surgery arm of EORTC 08941 trial.
N Engl J Med, 2023 Jun 28
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2018 Apr 16
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
The Lancet. Oncology, 2020 May 07
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Translational lung cancer research, 2019 Sep
Pathologic response after modern radiotherapy for non-small cell lung cancer.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2009 Aug 21
Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection.
Cancers, 2021 Sep 26
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.
Clinical lung cancer, 2023 Jul 25
Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" Era.
ERJ open research, 2020 Feb 17
International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?
Clinical Medicine Insights. Oncology, 2023 Feb 14
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer.
J Clin Oncol, 2019 Dec 06
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
Ann Oncol, 2020 Jul 05
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
J Thorac Oncol, 2021 Aug 19
A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L).
Clin Transl Sci, 2023 Feb 19
Brain exposure of osimertinib in patients with EGFRm NSCLC and brain metastases: a PET and MRI study.
J Clin Oncol, 2011 Nov 28
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.
J Clin Oncol, 2019 Jun 13
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
J Clin Oncol, 2022 Aug 12
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated .
J Thorac Oncol, 2023 Feb 23
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.
Future Oncol, 2021 Jul 19
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
BMC Cancer, 2019 Aug 19
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
The New England journal of medicine, 2023 Jun 04
Overall Survival with Osimertinib in Resected -Mutated NSCLC.
Chest, 2016-03
Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report.
Chest, 2008 Feb 08
Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer.
JAMA, 2010 Nov 24
Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial.
J Oncol Pharm Pract, 2018 Jun 05
Safety of dose-reduced pemetrexed in patients with renal insufficiency.
The New England journal of medicine, 2013-04-04
Hepatotoxicity with combination of vemurafenib and ipilimumab.
Ann Oncol, 2020 Jan 24
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Br J Cancer, 2020 Oct 05
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Transl Lung Cancer Res, 2022 Jul
Totality outcome of afatinib sequential treatment in patients with mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
JAMA Oncol, 2018 Aug 01
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
J Thorac Oncol, 2018 Mar 06
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
Journal of clinical pharmacology, 2018-12
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Investigational new drugs, 2023 Apr 13
Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
Case reports in oncology, 2021 Mar 01
Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.
JAMA Oncol,
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
The New England journal of medicine, 2023 Jun 03
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
Cancer journal (Sudbury, Mass.), 2020 Nov/Dec
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021 Feb 12
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Journal for immunotherapy of cancer, 2021 Aug
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
International journal of cancer, 2019 Feb 19
EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.
The Lancet. Respiratory medicine, 2023 May 05
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet (London, England), 2023 Dec 14
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Apr 22
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.

Related Topics in Medical Oncology

Copyright © 2024 theMednet
All Rights Reserved.